AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Evercore ISI Group Analyst Maintains Zimmer Biomet Holdings Rating, Lowers Price Target
ByAinvest
Tuesday, Jul 8, 2025 1:22 pm ET1min read
Evercore ISI Group analyst Vijay Kumar has maintained Zimmer Biomet Holdings' rating as "In-Line" while lowering the price target from $102 to $96, a 5.88% decrease. The average one-year target price for ZBH is $107.40, indicating a 16.02% upside from the current price of $92.57. The brokerage recommendation is "Hold" with an estimated GF Value of $143.28, suggesting a 54.78% upside from the current price.
Evercore ISI Group analyst Vijay Kumar has maintained Zimmer Biomet Holdings' rating as "In-Line" while lowering the price target from $102 to $96, a 5.88% decrease. The average one-year target price for ZBH is $107.40, indicating a 16.02% upside from the current price of $92.57. The brokerage recommendation is "Hold" with an estimated GF Value of $143.28, suggesting a 54.78% upside from the current price [1].In recent months, Zimmer Biomet has seen a series of adjustments to its price targets and ratings from various analysts. For instance, Morgan Stanley lowered its price objective on shares of Zimmer Biomet from $115.00 to $95.00 and set an "equal weight" rating for the company [1]. Similarly, Canaccord Genuity Group cut their price objective from $115.00 to $101.00 and set a "hold" rating for the company [1].
The company's latest earnings report showed strong performance, with earnings per share of $1.81, beating analysts' consensus estimates of $1.77 by $0.04 [1]. Zimmer Biomet reported a net margin of 11.86% and a return on equity of 12.73%. The company's revenue for the quarter was up 1.1% on a year-over-year basis, indicating robust growth.
Institutional investors and hedge funds have also shown interest in Zimmer Biomet, with several increasing their holdings in the company. For example, Dorsey & Whitney Trust CO LLC lifted its holdings by 2.3% in the 4th quarter, and MGO One Seven LLC increased its holdings by 5.1% during the same period [1].
Zimmer Biomet Holdings, Inc., operates as a medical technology company worldwide, designing, manufacturing, and marketing orthopedic reconstructive products, such as knee and hip products, S.E.T. products, craniomaxillofacial, and thoracic products [1].
References:
[1] https://www.marketbeat.com/instant-alerts/zimmer-biomet-nysezbh-given-new-9600-price-target-at-evercore-isi-2025-07-08/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet